Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

PET more accurate in assessing cancer treatment response

Mar 2008
Conventional imaging methods such as CT and MRI are used to measure sarcoma patients’ responses to treatment by evaluating size changes in the tumors. If the size is reduced, a patient is said to have responded positively to the treatment. If the size doesn’t change, clinicians may discontinue or change the treatment. However, recent evidence has shown that assessing treatment response by measuring changes in tumor size may not be accurate.

As reported in the Feb. 1 issue of Clinical Cancer Research, Dr. Fritz C. Eilber from the University of California, Los Angeles, and his colleagues evaluated whether measuring changes in glucose metabolic activity using PET would provide a more accurate analysis of treatment response than the traditional size-based methods.

The researchers tested 42 patients with soft tissue sarcomas (connective tissue tumors) who were scheduled to undergo neoadjuvant therapy (chemotherapy before surgery). The patients received PET and CT scans with a Siemens Biograph duo PET/CT scanner before and after the therapy. Whole-body CT scans were taken first, followed by PET an hour after an injection of the glucose tracer FDG. For a standard comparison, all of the tumors were histopathologically analyzed. Patients with tumors that showed at least 95 percent necrosis (cancer cell death) were considered histopathologic responders to the neoadjuvant therapy.

Eight of the patients responded positively to the therapy, according to histopathology. Only two of these showed a decrease in tumor size of more than 30 percent in CT images — the amount classified as a positive treatment response, according to standard evaluation criteria. However, PET images revealed significant changes in metabolic activity in all eight patients. The changes in glucose metabolic activity were significantly more pronounced in the histopathologic responders than in the nonresponders.

The researchers conclude that FDG-PET is more accurate in assessing treatment response to neoadjuvant therapy than to size-based criteria methods and therefore recommend PET for monitoring patients with soft tissue sarcomas.

BiophotonicsCTFrom The ClinicimagingMRI

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.